Fierce Pharma

FEBRUARY 14, 2024

Over the last month, for those watching HBO’s macabre “True Detective Night Country”—a TV series set in a harsh, sunless winter in a fictional Alaskan town—a continual theme is frostbite. | The FDA has approved the first medicine for severe frostbite. The U.S. regulator has signed off on Johnson & Johnson’s Aurlumyn (iloprost), an injected treatment to reduce the risk of amputation of the fingers or toes.

FDA 292

FDA Medicine 292

MedCity News

FEBRUARY 14, 2024

Ipsen’s Onivyde is now FDA approved as a first-line treatment for metastatic pancreatic cancer, triggering a milestone payment to Merrimack Pharmaceuticals, the drug’s original developer. Merrimack plans to dissolve operations but its shareholders will receive payouts from the Ipsen payment.

FDA 118

FDA Pharmaceutical Biopharma Pharma 118

Fierce Pharma

FEBRUARY 14, 2024

FDA unleashes multiple warning letters targeting insanitary manufacturing and online sales of unapproved Mounjaro, Ozempic fkansteiner Wed, 02/14/2024 - 05:10

Manufacturing 299

Manufacturing Sales FDA 299

MedCity News

FEBRUARY 14, 2024

When striving for health equity, organizations need to adopt new methods and a new mindset in order to steer clear of using SDoH as a buzzword, and instead hit the mark of health equity results.

112

112

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

FEBRUARY 14, 2024

With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion. | With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion.

Sales 259

Sales Medicine 259

MedCity News

FEBRUARY 14, 2024

Most hospitals and payers have publicly posted their pricing information, but experts think that data will remain mostly useless for consumers for at least another five years. Now that the data is available, healthcare software companies must step in and build tools that are personalized and easy to use. That way, consumers can eventually use price transparency data to shop for care.

Healthcare 112

Healthcare Healthcare 112

European Pharmaceutical Review

FEBRUARY 14, 2024

Gilead Sciences has agreed to acquire CymaBay Therapeutics for a total equity value of $4.3 billion. Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). This is based on data from the Phase III RESPONSE trial. The company shared that seladelpar is an oral, selective peroxisomeproliferator-activated receptor delta (PPARδ) agonist.

Transportation 97

Transportation Patients Pharma Leads 97

Fierce Pharma

FEBRUARY 14, 2024

Even as Australia’s CSL continues to grow, the company’s ambitions for its kidney disease and iron deficiency outfit Vifor Pharma—now known as CSL Vifor—have become more muted. | Even as Australia’s CSL continues to grow, the company’s ambitions for its kidney disease and iron deficiency outfit Vifor Pharma—now known as CSL Vifor—have become more muted.

Pharma 224

Pharma 224

European Pharmaceutical Review

FEBRUARY 14, 2024

The development of drug products containing live anaerobic bacterial strains as the active pharmaceutical ingredient and where potency and shelf-life is typically associated with viable cell quantification, poses unique challenges when compared to both small and large molecule development therapeutics. It is the uniqueness of the strain and perceived inter-cellular variations (sub-populations) resulting from high viable cell densities during growth (fermentation) and the subsequent harvest and d

Food and Drug Administration 97

Food and Drug Administration Manufacturing Engineering Pharmacology 97

Fierce Pharma

FEBRUARY 14, 2024

Sage Therapeutics and Biogen may not have the broad label that they had hoped for with Zurzuvae, but the two companies are still touting the med’s initial launch performance in postpartum depressio | Sage Therapeutics and Biogen may not have the broad label that they had hoped for with Zurzuvae, but the two companies are touting the med’s initial launch performance in postpartum depression.

FDA 201

FDA 201

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

European Pharmaceutical Review

FEBRUARY 14, 2024

A report by Allied Market Research predicts that the global pharmaceutical suspension market will reach $83.8 billion by 2032. Having valued $55.5 billion in 2022, the research expected that the market will reach a CAGR of 4.2 percent between 2023 and 2032. Factors driving the global pharmaceutical suspension market One of the main factors anticipated to propel the growth of the pharmaceutical suspension market is the availability of generic pharmaceutical suspensions, the research asserted.

Pharmaceutical 95

Pharmaceutical Marketing Medicine Healthcare 95

MedCity News

FEBRUARY 14, 2024

2024 presents an exciting yet challenging landscape for global pharma marketers. Prioritizing digital transformation, adopting patient-centric strategies, navigating regulatory complexities, investing in innovative content marketing, and fostering global collaboration position pharmaceutical marketers to make a lasting impact in an ever-evolving industry.

Marketing 102

Marketing Pharma Pharmaceutical Patients 102

pharmaphorum

FEBRUARY 14, 2024

Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients

FDA 101

FDA Patients 101

MedCity News

FEBRUARY 14, 2024

Omada’s newly expanded GLP-1 Care Track provides tailored exercise plans, support for getting off of GLP-1s and calorie tracking. It also offers insight into who is responding to GLP-1s and who is engaging in Omada’s program.

Management 102

Management 102

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

PharmaTimes

FEBRUARY 14, 2024

The aggressive type of cancer accounts for 13% of all lung cancer cases worldwide

133

133

MedCity News

FEBRUARY 14, 2024

Here’s the audio of Episode 1 of the newly-launched show Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare.

Healthcare 102

Healthcare Healthcare Biopharma 102

pharmaphorum

FEBRUARY 14, 2024

Eicos Sciences' Aurlumyn has become the first FDA-approved drug treatment to prevent amputations in cases of severe frostbite

FDA 100

FDA 100

MedCity News

FEBRUARY 14, 2024

A comprehensive approach to obesity management goes beyond prescribing medications for a quick fix.

Medical 105

Medical Management Physicians Healthcare 105

Advertisement

Pharmaceutical Technology

FEBRUARY 14, 2024

A bipartisan group of lawmakers is seeking an investigation and sanctions against WuXi given alleged connections to the Chinese military.

78

78

PharmaTimes

FEBRUARY 14, 2024

The report includes five recommendations for the government to address these issues

Government 90

Government Medical science Medical 90

pharmaphorum

FEBRUARY 14, 2024

Venture capital group Earlybird has launched its second health fund with $185 million to fund companies in the health technology area

64

64

Nixon Gwilt Law

FEBRUARY 14, 2024

Tracking technologies (pixels, cookies, etc.) are invisible and everywhere. Offered by Meta’s Pixel and Google Analytics, and by many social media platforms like Instagram and TikTok, tracking technologies are the workhorse behind tailored advertising (e.g., behavioral advertising) and marketing analytics on consumer-facing websites. Tracking technologies capture static and behavioral information about webpage visitors, such as click-through rate, location, and other user input, including person

Marketing 52

Marketing Healthcare Healthcare Healthcare Provider 52

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Clarivate

FEBRUARY 14, 2024

In an increasingly digital world, the amount of data generated around the use of medical devices provides opportunities for medtech companies to gain valuable insights about patients and their physicians. However, without context, those data are not sufficient to recognize what is actually happening in the market and why. To understand the environment in which these devices are functioning and provide a high-touch, personalized experience, marketers require a combination of robust external, comp

Physicians 52

Physicians Education Patients Healthcare 52

Nixon Gwilt Law

FEBRUARY 14, 2024

Tracking technologies (pixels, cookies, etc.) are invisible and everywhere. Offered by Meta’s Pixel and Google Analytics, and by many social media platforms like Instagram and TikTok, tracking technologies are the workhorse behind tailored advertising (e.g., behavioral advertising) and marketing analytics on consumer-facing websites. Tracking technologies capture static and behavioral information about webpage visitors, such as click-through rate, location, and other user input, including person

Marketing 52

Marketing Healthcare Healthcare Healthcare Provider 52

Pharmaceutical Commerce

FEBRUARY 14, 2024

Onivyde (irinotecan liposome injection) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) was found to improve overall survival in metastatic pancreatic adenocarcinoma.

FDA 52

FDA 52

PM360

FEBRUARY 14, 2024

Public Health Leader, Dr. Dave A. Chokshi, Becomes New Board Member of Yuvo Health Dr. Dave A. Chokshi Dr. Dave A. Chokshi, a nationally renowned public health leader, practicing primary care physician, and Sternberg Family Professor of leadership at the City College of New York, has joined the board of Yuvo Health, a leading technology, operational, and administrative solution uniquely designed to give community health centers an advantage in value-based care.

Leads 52

Leads Medicine Physicians Training 52

Advertisement

Distribution

Pharmaceutical Commerce

FEBRUARY 14, 2024

Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.

Marketing 52

Marketing 52

PharmaVoice

FEBRUARY 14, 2024

The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

Pharma 52

Pharma 52

Pharmaceutical Commerce

FEBRUARY 14, 2024

Bruce Phelan of Blue Fin discusses Novo Nordisk's purchase of Catalent manufacturing sites to increase its ability to meet the demand for the popular weight loss drug Wegovy.

Manufacturing 52

Manufacturing 52

Pharmaceutical Technology

FEBRUARY 14, 2024

The US FDA has granted fast track designation to Edgewise Therapeutics’ EDG-5506 aimed at treating Duchenne muscular dystrophy.

FDA 59

FDA 59

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales